CARD14-associated papulosquamous eruption
There are fewer than 40 cases reported in the literature to date. It is likely that the prevalence of CAPE is higher than stated, given that genetic testing may not have been performed on many patients with treatment refractory to psoriasis and PRP.
CAPE is caused by gain of function mutations in the CARD14 gene, which is expressed in epithelial cells and keratinocytes. The CARD14 gene is involved with activating the nuclear factor kappa B (NF-κB) pathway and increasing downstream inflammatory interleukins and intermediates, such as interleukin (IL)-17, IL-22, and IL-23.
L41.8 – Other parapsoriasis
22585003 – Papulosquamous dermatosis
- Seborrheic dermatitis
- Pityriasis rubra pilaris
- Erythrokeratodermia variabilis
- Progressive symmetric erythrokeratoderma
- Atopic dermatitis
- Congenital nonbullous ichthyosiform erythroderma
- Mycosis fungoides
- Acrodermatitis enteropathica